Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon®

Contraception

Volumn 58, Issue 5, 1998, Pages 283-288

  Wenzl, René ^a   Van Beek, Agaath ^b   Schnabel, Peter ^b   Huber, Johannes ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b NV ORGANON   (Netherlands)

Author keywords

3 ketodesogestrel; Contraceptive implant; Etonogestrel; Implanon ; Pharmacokinetics

Indexed keywords

ETHYLENE VINYL ACETATE COPOLYMER; ETONOGESTREL;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG RELEASE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; SUBCUTANEOUS DRUG ADMINISTRATION;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, PROGESTIN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE IMPLANTS; CONTRACEPTIVE METHODS; FAMILY PLANNING; PROSPECTIVE STUDIES; RESEARCH METHODOLOGY; RESEARCH REPORT; STUDIES;

ABSORPTION; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DRUG IMPLANTS; FEMALE; HALF-LIFE; HUMANS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; VINYL COMPOUNDS;

EID: 0032412169     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(98)00110-3     Document Type: Article

References (6)

1. Mäkäräinen L., van Beek A., Tuomivaara L., Asplund B., Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant Implanon compared with Norplant . Fertil Steril. 69:1998;714-721.
2. Kuhl H., Jung-Hoffmann C., Heidt F. Serum levels of 3-ketodesogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel. Contraception. 38:1988;381-390.
3. Sheiner LB. ELSFIT (version 3.1). A program for the extended least squares fit to individual pharmacokinetic data. Users Manual. Technical Report of the Division of Clinical Pharmacology, University of California, San Francisco, CA 94143, USA. January 1983.
4. Popli H., Sharma S.N., Collett J. In vivo evaluation of biodegradable norethindrone implants. (abst) J Pharm Pharmacol. 49:(suppl 4):1997;68.
5. Fotherby K. Levonorgestrel clinical pharmacokinetics . Clin Pharmacokinet. 28:1995;203-215.
6. Sivin L. I, ähteenmäki P., Mishell D.R. Jr, et al. First week drug concentrations in women with levonorgestrel rod or Norplant® capsule implants. Contraception. 56:1997;317-321.